Department of Medicine 3 – Rheumatology and Immunology

TGFβ PROMOTES FIBROSIS BY MYST1-DEPENDENT EPIGENETIC REGULATION OF AUTOPHAGY (2018) Zehender A, Lin NY, Stefanica A, Chen CW, Soarel A, Wohlfahrt T, Reuber S, et al. Conference contribution THE AP1 TRANSCRIPTION FACTOR CJUN AMPLIFIES HEDGEHOG-INDUCED FIBROBLAST ACTIVATION AND TISSUE FIBROSIS (2018) Bergmann C, Merlevede B, Beyer C, Hallenberger L, Brandt A, Dees C, Pötter S, et al. Conference contribution TOCILIZUMAB ACHIEVES BETTER REPAIR OF FOCAL BONE EROSIONS THAN TUMOUR NECROSIS FACTOR INHIBITION IN RA PATIENTS - DATA FROM THE PROSPECTIVE REBONE STUDY ON EROSION REPAIR (2018) Schett G, Finze S, Kraus S, Regensburger A, Kocijan R, Rech J Conference contribution What Characterizes Osteoarthritis: Ultrasound-Detected Inflammation but Not Osteophytes Is More Common in Hand Osteoarthritis Than in Painless Bony Enlargements (2018) Gasperi N, Adinolfi A, Kleyer A, Hagen M, Gasperi C, Weger M, Kiechl S, et al. Conference contribution Secukinumab Efficacy in Psoriatic Arthritis: Individual Patient Meta-Analysis of Four Phase 3 Trials in 2049 Patients (2018) Gottlieb AB, Mease PJ, Kirkham B, Nash P, Balsa A, Combe B, Rech J, et al. Conference contribution SECUKINUMAB EFFICACY IN PSORIATIC ARTHRITIS PATIENTS WITH OR WITHOUT ENTHESITIS AT BASELINE - POOLED ANALYSIS FROM TWO PHASE-III TRIALS OVER 2 YEARS (2018) Wallman JK, Schett G, Mcinnes IB, Quebe-Fehling E, Rasouliyan L, Pricop L, Fasth AE, Gaillez C Conference contribution The Influence of Hand Osteoarthritis on Bone Microstructure and Biomechanical Properties of Radial Bone (2018) Simon D, Unbehend S, Bayat S, Rech J, Hueber A, Schett G, Kleyer A Conference contribution Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: Long-Term (4-Year) Data from a Phase 3 Study (2018) Mcinnes IB, Kivitz AJ, Nash P, Rahman P, Rech J, Kirkham B, Navarra SV, et al. Conference contribution Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial (2018) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution SECUKINUMAB EFFICACY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: META-ANALYSIS OF 4 PHASE 3 TRIALS (2018) Mease P, Kirkham B, Nash P, Balsa A, Combe B, Rech J, Martin R, et al. Conference contribution